drugset
drugset / Trial / NCT00806728

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

NCT00806728 ↗

Phase 1 Completed 17 enrolled MedImmune LLC
RandomizedSingle-groupOpen-labelTreatment

Summary

A clinical trial to assess safety and two regimens of (MEDI-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute Graft-versus-Host Disease.

Timeline

Start
1998-05
Primary completion
1998-11
Completion
1998-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Siplizumab Monoclonal antibody 0.12 mg/kg —

Indications

acute graft versus host disease cancer